Metropolis Healthcare Ltd
NSE:METROPOLIS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
100.6B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
98.2B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
63.3B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
75.7B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
29.2B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
24.3B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.5B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.8B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
12B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Metropolis Healthcare Ltd
Glance View
Metropolis Healthcare Ltd., a pioneer in the diagnostics industry, embarked on its journey in 1980 under the visionary leadership of Dr. Sushil Kanubhai Shah. This Mumbai-based company quickly established itself as a trusted name, offering a comprehensive range of diagnostic services, including pathology tests, radiology, and wellness solutions. The heart of its operations lies in its expansive network of laboratories and collection centers strategically distributed across India and several international locations. By leveraging state-of-the-art technology and maintaining rigorous quality standards, Metropolis has positioned itself as a forerunner in providing precise and reliable medical test results. This was especially crucial as the demand for accurate healthcare diagnostics surged, driven by an increasingly health-conscious population. Metropolis generates its revenue primarily through fees charged for its broad spectrum of diagnostic tests that cater to a variety of health needs, from routine screenings to specialized, high-complexity tests. Its business model capitalizes on partnerships with healthcare providers, hospitals, and corporations, offering customized health packages and diagnostic solutions that ensure a steady flow of clientele. By integrating advanced testing technologies and continuously expanding its service portfolio, the company taps into diverse revenue streams, which include corporate wellness programs and home health services. This diversified approach not only enhances its financial stability but also solidifies its reputation as a go-to healthcare partner for individuals, corporate clients, and healthcare institutions alike.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Metropolis Healthcare Ltd is 10.7%, which is below its 3-year median of 11.2%.
Over the last 3 years, Metropolis Healthcare Ltd’s Net Margin has decreased from 12.8% to 10.7%. During this period, it reached a low of 10.6% on Mar 31, 2024 and a high of 12.8% on Dec 31, 2022.